Navigation Links
Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis

infiltrate and clinical scores, AN2728-treated plaques improved significantly compared with vehicle treatment (p<0.001), and efficacy was comparable to that seen with betamethasone and tacrolimus. AN2728 treatment was well-tolerated in all patients.

About Psoriasis

Psoriasis is an inflammatory skin disorder that affects approximately 14 million individuals worldwide. The disorder ranges from a single, small, localized lesion in some patients to a severe, disfiguring skin condition that may be associated with disabling arthritis.

About Anacor Pharmaceuticals

Anacor, a privately held, clinical-stage pharmaceutical company, is developing novel product candidates for inflammatory, fungal and bacterial diseases based on its proprietary, small-molecule, boron-based chemistry. The company's lead product is AN2690, which is in Phase 2 trials for onychomycosis, a fungal infection of the nail and nailbed. Ancor has entered into an exclusive, worldwide agreement with Schering-Plough Corporation to develop and commercialize the drug. The company is also conducting clinical trials with two anti-inflammatory product candidates, AN2728 and AN0128

CONTACT: David Perry, Chief Executive Officer of Anacor Pharmaceuticals,+1-650-739-0700; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, , for Anacor PharmaceuticalsInc. breid@weisscommpartners.com

Web site: http://www.anacor.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2

Related medicine technology :

1. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:11/28/2008)... Germany, November 28 German biote...hip in specialized HIV monitoring and,AIDS patien...g countries. In,the year 2008, 2.5 million patien...bust and highly affordable "CyFlow" system, suppor...th HIV/AIDS. Due to introduction of the,Partec in...
(Date:11/26/2008)...nn., Nov. 26 Children w...significantly increased risk of developing mental ...of a Mayo Clinic study published this month in Pe...ademy of Pediatrics. , , The retrospective ... with strabismus (misaligned eyes) and compared th...
(Date:11/25/2008)...ness can improve recovery , , Audio and Web...able on the Mayo Clinic News Blog. Please see the ... ROCHESTER, Minn., Nov. 25 /PRNewswire-USNewswire...e patients don,t think they,re having a stroke -- ...heir condition worsens. The findings appear in the...
(Date:11/25/2008)...NCISCO, Calif., Nov. 25 Proteolix,...of novel therapeutics that target,protein degrada...oday,announced that data from two ongoing Phase 2...ma will be presented at the upcoming 50th Annual M...). Carfilzomib is the first in a new class,of sp...
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 1Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 2Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 3Fund Manager Joins Board of GSI Securitization Inc 1368 1Fund Manager Joins Board of GSI Securitization Inc 1368 2Billians HealthDATA GM Speaking on Dreamforce 07 Panel 1363 1Billians HealthDATA GM Speaking on Dreamforce 07 Panel 1363 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 1CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 3
...P-1 in Neuropathic Pain, TARRYTOWN, N.Y., May 03, ... announced today that it will present new data for...26th Annual,Scientific Meeting of the American Pai...ented topical cream formulation of two,FDA-approve... a,product candidate intended for use in the manag...
...nal Conference on Antiviral,Research, SAN DIEGO, M...rmaceuticals, Inc. , a biopharmaceutical research ... proprietary product,candidates for the treatment ... that it presented results demonstrating synergist...d flu) viruses when,the Company,s broad-spectrum a...
Other Medicine Technology:EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 2EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 3EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 4EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 5ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 2ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 3
(Date:12/2/2008)... NDA with FDA in Early to Mid-2009 , , WARR...velopers of PharmFilm(R) technology and a drug del... pharmaceutical products, and Strativa Pharmaceuti...rmaceutical Companies, Inc. (NYSE: PRX ), today ... bioequivalence studies for a thin film formulatio...
(Date:12/2/2008)...c. 2 With the bright lights, sweet...holidays may be an exciting time of year for any c..., especially with today,s tough economy. Whether ...ptying their wallets, or spending hours traveling ...elax, and even less time to be alone and romantic ...
(Date:12/2/2008)...Dec. 2 Aduromed Industri...ovider of medical waste treatment,systems, today ... on November,24, 2008 to protect the Company,s pr...nerized MedClean Systems that provide a turnkey so...zation and volume reduction. , The patent a...
(Date:12/2/2008).... 2 Mylan Inc. (NYSE: ... Mylan Pharmaceuticals Inc., have entered,into a ... Corp., Novartis,Corp. and Novartis International...sion of Novartis, Femara(R). , Mylan,s Vice...re very,pleased to have reached this agreement, w...
Breaking Medicine News(10 mins):Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 2Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
... the risk of diabetes in the Indigenous population...ott, Pro-vice Chancellor of the Division of Health...ows that while clinical care of adults with diabet...ndigenous Australians are developing the disease. ...
... epidemic of diabetes in the US is out. Spending o.... According to a drug trend report released by th...ailed only cholesterol medications in total prescr...n 2006. An aging population and the alarming rise...
...disfiguring accident that nearly killed him, but h...s home on Andrews Air Force Base in Maryland. N...e, that is, because of his brand-new nose. In a s... over a year-long period that ended with removal o...
...al Boston) and colleagues have identified the canc... soft-tissue sarcoma of childhood. 'Identifying ...ved genetic programs underlying self-renewal in ER... into how to destroy these cell types in establish...
Other Medicine News:Health News:Spending on Diabetes Drugs Soars in US 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 3Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 4Health News:Pediatric Cancer Stem Cell Identified 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)
Used for stone manipulation and removal in the urinary tract. Supplied sterile in peel-open packages. Intended for one-time use.
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
BARDEX Red Rubber Urethral Catheter (Robinson Model)
Medicine Products: